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Abstract
Pregnant and lactating women and breastfed infants are at risk of vitamin D deficiency. The supplemental vitamin D dose that optimises
maternal vitamin D status and breast milk antirachitic activity (ARA) is unclear. Healthy pregnant women were randomised to 10 (n 10), 35
(n 11), 60 (n 11) and 85 (n 11) µg vitamin D3/d from 20 gestational weeks (GW) to 4 weeks postpartum (PP). The participants also received
increasing dosages of fish oil supplements and a multivitamin. Treatment allocation was not blinded. Parent vitamin D and 25-hydroxyvitamin D
(25(OH)D) were measured in maternal plasma at 20GW, 36GW and 4 weeks PP, and in milk at 4 weeks PP. Median 25(OH)D and parent
vitamin D at 20GW were 85 (range 25–131) nmol/l and ‘not detectable (nd)’ (range nd–40) nmol/l. Both increased, seemingly dose dependent,
from 20 to 36GW and decreased from 36GW to 4 weeks PP. In all, 35µg vitamin D/d was needed to increase 25(OH)D to adequacy (80–
249nmol/l) in >97·5% of participants at 36GW, while >85µg/d was needed to reach this criterion at 4 weeks PP. The 25(OH)D increments from
20 to 36GW and from 20GW to 4 weeks PP diminished with supplemental dose and related inversely to 25(OH)D at 20GW. Milk ARA related to
vitamin D3 dose, but the infant adequate intake of 513 IU/l was not reached. Vitamin D3 dosages of 35 and >85µg/d were needed to reach
adequate maternal vitamin D status at 36GW and 4 weeks PP, respectively.
Key words: Adequate intake: Antirachitic activity: Breast milk: Pregnancy: Supplements: Vitamin D
Vitamin D deficiency and insufficiency are worldwide problems.
Among the vulnerable groups are pregnant and lactating women
and their exclusively breastfed infants(1,2). Low vitamin D status is
associated with a wide range of risk factors/diseases in both
pregnant women and their infants. Some of these associations
have not been consistently found(3). Although recently more trials
and meta-analyses have been published, the clinical relevance of
higher serum 25-hydroxyvitamin D (25(OH)D) during pregnancy
and/or supplementing pregnant women with vitamin D is still
unclear(4,5). There is increasing evidence that adequate vitamin D
status may reduce the risk of pre-eclampsia(4,6), low birth
weight(7,8) and preterm birth(7,9) and increase newborn length
and head circumference(4,10).
Plasma 25(OH)D is the widely accepted vitamin D status
parameter. Commonly employed cut-off values are <25–
30nmol/l for vitamin D deficiency, 25 or 30–50nmol/l for
vitamin D insufficiency and >50 nmol/l for vitamin D suffi-
ciency(11,12). Many vitamin D experts consider 25(OH)D levels
between 50 and 75 or 80 nmol/l as hypovitaminosis D and
between 75 or 80 and 250 nmol/l as vitamin D sufficiency(13–15).
Dependent on definition, it is estimated that the worldwide
prevalence of vitamin D deficiency and insufficiency during
pregnancy ranges from 8 to 100%(16). The RDA for pregnant and
lactating women is identical to that of non-pregnant adults up to
70 years. They range from 10 µg/d (Health Council of the
Netherlands(17)) to 15 µg/d (Institute of Medicine (IOM)(11)).
However, the median dietary vitamin D intake of Dutch women
of 19–30 years is only 2·6 µg/d(18). Since it is difficult to reach the
RDA from unfortified dietary sources and because of the con-
sequences for both mother and infant, the Health Council of
the Netherlands advices pregnant women to take a 10 µg/d
vitamin D supplement, starting preferably before conception(17).
The current RDA of 10–15 µg might be insufficient to reach
50 nmol/l 25(OH)D in 97·5% of the women by the end of
pregnancy. This can be concluded from two recent randomised
controlled trials (RCT) conducted in pregnant women in New
Zealand(19) and in Canada(20), with median baselines of 55 and
64–68 nmol/l 25(OH)D, respectively, at enrolment in the
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; AI, adequate intake; ARA, antirachitic activity; GEE, generalised estimation equation; IOM, Institute of
Medicine; nd, not detectable.
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second trimester. The RCT used 2000 IU (50 µg), 1000 IU (25 µg)
or 0 IU (placebo) supplemental vitamin D/d (New Zealand), or
2000 IU (50 µg), 1000 IU (25 µg) or 400 IU (10 µg) vitamin D/d
(Canada). In all, 11, 9 and 50%, respectively, of the women in
New Zealand and 3, 12 and 7% (analysis ‘as treated’) of the
Canadian women exhibited vitamin D insufficiency (25(OH)D
< 50 nmol/l) at 36GW. Thus, it seems that, dependent on
baseline 25(OH)D and compliance, a vitamin D supplement of
about 50 µg/d may be appropriate to reach 50 nmol/l 25(OH)D
in about 97·5% of women by the end of pregnancy.
Postnatal infant vitamin D sources include stores, exposure to
sunlight and breast milk or formula. Early measurements of
breast milk vitamin D conducted in the 80s showed that breast
milk contains both the parent vitamin D and 25(OH)D, which
are usually summed to the so-called antirachitic activity (ARA, in
IU/l)(21,22). The IOM vitamin D adequate intake (AI) by infants
of 0–6 months amounts to 10 µg/d(11). This AI is based on some
studies in Western countries, showing that 10 µg/d maintains
infant serum 25(OH)D at 40–50 nmol/l in the first postnatal year
and thereby supports normal bone accretion(11). A 10 µg/d
intake translates to a milk ARA of 513 IU/l at an average mature
milk consumption of 780ml/d(23). However, breast milk ARA of
Western mothers ranges from 8 to 331 IU/l(24–26). Even mature
milk ARA of women with high vitamin D status from year-long
abundant sunlight exposure does not reach the IOM AI(27).
Currently, in most Western countries it is recommended to
supplement breastfed infants with 10 µg vitamin D/d(17,28,29).
It is at present unclear what maternal vitamin D dose is
needed to reach the IOM AI of 513 IU/l in milk. In the afore-
mentioned New Zealand trial, published during the course of
our study, Wall et al.(30) showed that 2000 IU (50 µg) vitamin D,
administered during both pregnancy and lactation, results in a
milk ARA of 64 (23–197) IU/l at 2 weeks PP. The only study
successful in reaching the IOM AI was published by Wagner
et al.(31). They showed that supplementation of lactating
women with 6400 IU (160 µg) vitamin D/d for 6 months
increases milk ARA to 873 IU/l at the study end. The corre-
sponding mean plasma 25(OH)D of their exclusively breastfed
infants was about 113 nmol/l and thereby similar to that of the
offspring of unsupplemented mothers receiving 7·5 µg vitamin
D/d from 1 month PP. This was confirmed in a large RCT in
which a maternal intake of 6400 IU supplied the nursing infant
with sufficient vitamin D to mimic the 25(OH)D concentrations
to counterparts receiving a daily 400 IU oral vitamin D supple-
ment(32). However, although perfectly safe, with no adverse
effects observed, a daily 160 µg vitamin D dose is well above the
current upper limit of 100 µg/d(33).
A strategy merely aiming at the postnatal period provides no
benefits for the mother and her developing child during preg-
nancy. Vitamin D supplementation during pregnancy is likely to
support the building of fetal vitamin D stores. Notwithstanding
low milk ARA, we observed that exclusively breastfed infants of
unsupplemented African mothers with lifetime abundant sun-
light exposure have plasma 25(OH)D above 50 nmol/l. This
suggested mobilisation of vitamin D from infant stores, since
major sources from sunlight exposure and other vitamin D
sources were unlikely at that stage(27,34,35). As the primary
aim of our ‘ZOOG-MUM’ trial, we investigated what
maternal ‘parent vitamin D’ (the sum of cholecalciferol and
ergocalciferol) and 25(OH)D concentrations are needed to
reach plasma 25(OH)D of 80 nmol/l by supplementing preg-
nant Dutch women with various vitamin D3 dosages from
20GW up to 4 weeks PP. We were notably interested to see the
corresponding milk ARA that will be reached.
Methods
Study design
This was a randomised trial called ZOOG MUM conducted in
Groningen, the Netherlands. The study design has previously
been detailed(36). In brief, healthy pregnant women received
increasing doses of vitamin D3, together with a multi-vitamin
and increasing doses of fish oil from 20GW until 4 weeks PP.
The Ethics Committee of the University Medical Center Gro-
ningen (UMCG) (METc number 2014·263) approved the study.
The study was registered in The Netherlands National Trial
Register (Trial ID NTR4959). All women provided written
informed consent. The study was in agreement with the
Helsinki Declaration of 1975 as revised in 2013.
Power analysis
In the study of Grootheest et al.(37), non-pregnant adults in the
Netherlands had 68·0 (SD27·2) nmol/l plasma 25(OH)D.
Vieth(15) and Wagner et al.(31) showed that 1 µg oral vitamin D3/d
increases plasma 25(OH)D with 0·4–1·0nmol/l. Based on
these data, we expected a 23–75nmol 25(OH)D/l difference
between the lowest and highest supplemental groups. Earlier
studies by Luxwolda et al.(38) in Tanzania showed that non-
pregnant adults had a 25(OH)D of 106·8 (SD28·4) nmol/l.
Combining the data of Grootheest et al. and Luxwolda et al., we
performed a power analysis showing that differences in 25(OH)D
between two groups of six subjects with 25(OH)D of 68·0nmol/l
(Grootheest et al.) and 107nmol/l (Luxwolda et al.), respectively,
should be detectable with 80% power at P< 0·05. We expected
the dropout percentages to be <52%, as observed in a previous
study by Van Goor et al.(39). We consequently aimed at an
inclusion of 10–11 women per group.
Study population
From December 2014 until December 2015, forty-three appar-
ently healthy women in the first trimester of a singleton preg-
nancy, all living in the Netherlands, agreed to participate in the
trial. Their recruitment took place at six obstetric practices in the
provinces of Groningen, Drenthe and Friesland (the Nether-
lands) via leaflets spread by ‘Moeders voor Moeders’ (transla-
tion: ‘Mothers for Mothers’) and posters in the city of
Groningen. The women were randomly allocated to four
groups (Fig. 1) using block randomisation. The participants
were aware of the composition and the nutrient dosages in the
multivitamins, fish oil capsules and vitamin D3 capsules (see
‘Supplements’ below). Exclusion criteria were as follows:
hyperemesis gravidarum, vegetarian/vegan diet, not having the
intention to exclusively breastfeed after delivery, pre-pregnancy
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BMI >29 kg/m2 and pregnancy complications or preterm
delivery after inclusion.
Supplements
The supplements, daily dosages and the number of capsules
and tablets taken by women in the four dosage groups are
shown in Table 1. All participants received a multivitamin
supplement (Omega Pharma) providing 10 µg vitamin D3 and
12–125% of the Dutch RDA/AI for vitamins and minerals for
pregnant and lactating women. In addition, the participants
took 0, 25, 50 and 75 µg vitamin D3 and 225 + 90, 450 + 180,
675 + 270 and 900 + 360mg EPA and DHA in groups A, B, C
and D, respectively. Taken together, we chose the daily total
dosages of vitamin D3 of 10, 35, 60 and 85 µg. These are in
between the vitamin D recommendation of 10 µg/d(17,28,29) and
the current upper limit of 100 µg/d(33). The vitamin D3 and fish
oil supplements were supplied by Bonusan. All mothers, allo-
cated to groups A, B, C and D reported adherence to the pro-
tocol. They took >75% of the supplements, as recorded by
inquiry at appointment, by questionnaire or both.
Sample collection and storage
Information on maternal and infant characteristics, socio-
economic status, supplement use and sunlight exposure was
gathered by questionnaires at 20GW and/or 4 weeks PP. We
collected 24 h urine samples and non-fasting venous EDTA–
blood and lithium-heparin-anticoagulated blood at the study
start, 20GW, 36GW and 4 weeks PP. A milk sample was col-
lected at 4 weeks PP. Blood samples were processed to plasma
by centrifugation and stored at –20°C until analysis. The 24 h
urine volume was measured and a sample was stored at –20°C
until analysis. The participants were instructed to collect the
full amount of breast milk from a single breast around noon
(10·00–14·00 hours) on the day before, or on the day of, blood
sampling, using a standardised protocol. The milk was collected
either manually or using a breast milk pump. To ensure
homogenisation, they were carefully swerved and subsequently
transferred to two sampling tubes. The milk samples were
stored in the participants’ freezer. On the sampling day, they
were transported to the UMCG in a ‘cool transport container’ for
frozen specimens (Sarstedt; mailing containers). Upon arrival,
they were immediately stored at –20°C until analysis.
Analyses
The milk vitamin D profile (vitamin D3, vitamin D2, 25(OH)D3
and 25(OH)D2) was analysed by liquid chromatography–
tandem MS (LC–MS/MS). The method includes saponification(40)
and derivatisation with 4-(2-(3,4-dihydro-6,7-dimethoxy-
4-methyl-3-oxo-2-quinoxalinyl)ethyl)-3H-1,2,4-triazole-3,5(4H)-
dione(41). The inter- and intra-assay CV at 1·7–34·8 nmol/l were
<15 and <10%, respectively, for all four analytes. The quanti-
fication limit was 0·1 nmol/l for vitamin D and 0·2 nmol/l for
25(OH)D. Milk and EDTA plasma vitamin D3 and vitamin D2
were summed to vitamin D, and 25(OH)D3 and its 25(OH)D2
analogue were combined to 25(OH)D. For milk ARA calcula-
tion, we assumed that 1 IU/l equals 25 pg/ml vitamin D and
5 pg/ml 25(OH)D. EDTA plasma 25(OH)D was measured with
isotope dilution online solid phase extraction LC–MS/MS, as
described by Dirks et al.(42) EDTA plasma vitamin D was analysed
using a modification of this method. These included the use of an
additional derivatisation with 4-phenyl-1,2,4-triazoline-3,5-dione
First visit:
20 GW
Randomly assigned (n 43)
Group A Group B Group C Group D
Multivitamin (10 μg vitamin D)






Blood only (n 2) Blood only (n 1)















Disliked supplements (n 1)
Pregnancy bleeding (n 1)
Drop out:
Excluded:
Disliked supplements (n 1)
Use of anticoagulants (n 1)
Excluded:
Pregnancy hypertension (n 1)
Gestational diabetes (n 1)
Multivitamin (10 μg vitamin D)
25 μg vitamin D
450 mg DHA, 180 mg EPA
(n 11)
Multivitamin (10 μg vitamin D)
50 μg vitamin D
667 mg DHA, 270 mg EPA
(n 11)
Multivitamin (10 μg vitamin D)
75 μg vitamin D







Disliked supplements (n 1)
Fig. 1. Flow chart of the initially forty-three participating women. Pregnant women were supplemented from 20 gestational weeks (GW) to 4 weeks postpartum (PP).
Blood samples were taken at 20 and 36GW and at 4 weeks PP. A milk sample was taken at 4 weeks PP.
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and the employment of a Supelco Ascentis Express F5; 2·7 µm;
2·1× 50mm column. The inter-assay and intra-assay CV for
25(OH)D were <15 and <10% at 25–150 nmol/l, and <15 and
<10% for vitamin D at 11–57 nmol/l, respectively. The limits of
quantification were 4·0 and 4·4 nmol/l for 25(OH)D and vitamin
D, respectively. Plasma (lithium heparin) Ca and phosphate and
urine Ca and creatinine were analysed with validated automatic
routine laboratory methods (Roche Modular).
Employed cut-off values for vitamin D status
Cut-off values of 25, 50, 80 and 250 nmol/l 25(OH)D were
employed for vitamin D deficiency (<25 nmol/l), vitamin D
insufficiency (25–49nmol/l), hypovitaminosis D (50–79nmol/l),
vitamin D sufficiency (80–249nmol/l) and potential vitamin D
toxicity (>250nmol/l). We chose 25 over 30 nmol/l as this is a
widely used cut-off for vitamin D deficiency(12,14,43). We chose
80, rather than 50nmol/l 25(OH)D since, based on lowest
parathyroid hormone (PTH) and osteoporosis fractures, 25(OH)D
>80nmol/l is considered optimal by vitamin D experts(14,44).
Data analysis and statistics
The IBM PASW Statistics 22 and STATA, version 12 software
were used. Since not all data were Gaussian distributed, we
report medians and ranges. Total between-group differences
were analysed with the Kruskal–Wallis test for continuous data
and χ2 test for nominal data. Between-group differences were
analysed by Kruskal–Wallis pairwise comparison with post hoc
Bonferroni correction for continuous data. A P value <0·05 was
considered significant. Between time point differences were
analysed using a Wilcoxon signed-rank test. Following Bon-
ferroni correction, a P value <0·0167 was considered significant.
The association between plasma 25(OH)D and other para-
meters was evaluated via generalised estimating equations
(GEE) in a repeated and stepwise fashion. First, plasma
25(OH)D results at the various visits were subtracted from the
result of the first visit (20GW). These changes were analysed for
normality using the Shapiro–Wilk test. Subsequently, the GEE
model was constructed in which 25(OH)D changes were
associated with the following independent parameters: visit,
visit2 (to analyse a potential parabolic relationship in time),
group (depending on the dosing of vitamin D3), month
and month2 (to acknowledge the non-linear fit by month on the
plasma 25(OH)D) concentration, baseline plasma 25(OH)D
and also potential confounding factors being age, year, BMI,
BMI at delivery, sex, birth weight, pregnancy duration (d),
lactation duration (d), estimated time spent outside in direct
sunlight during weekdays and time spent outside in
direct sunlight during the weekend. A check was performed
on the relationship between baseline 25(OH)D and month of
year to avoid a potential interaction between these
parameters. No such relationship was observed with the current
data set (P> 0·25). A P value <0·05 was considered significant.
Table 1. Dose of daily supplements per group
Group A B C D
Vitamin D3 (µg) 10 (in multivitamin) 35 (25 + 10) 60 (50 + 10) 85 (75 + 10)
No. of vitamin D3 capsules 0 1 2 3
DHA+EPA (mg) 225 + 90 450+ 180 675+ 270 900+ 360
No. of fish oil capsules 1 2 3 4
Multivitamin containing
β-Carotene (µg) 1200
Vitamin B1 (mg) 1·1
Vitamin B2 (mg) 1·4
Vitamin B3 (mg) 16
Vitamin B5 (mg) 6
Vitamin B6 (mg) 1·4
Vitamin B8 (µg) 50
Vitamin B11 (µg) 400
Vitamin B12 (µg) 2·5
Vitamin C (mg) 40
Vitamin D3 (µg) 10











No. of multivitamin tablets 1 1 1 1
Total no. of capsules and tablets 2 4 6 8
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The flow chart of the included women is shown in Fig. 1. Of the
forty-three included women, thirty-eight completed the study. In all,
two were excluded due to late pregnancy complications. Of the
remaining thirty-six, three discontinued breast-feeding before
4 weeks PP. Only one mother provided us with a breast milk sample
but not with other samples at 4 weeks PP. Plasma parent vitamin D
concentration below the limits of quantification were evaluated as
such. Assigning these to zero did not alter our conclusions.
Baseline characteristics
Table 2 shows the characteristics of the investigated mothers
and their infants. The median maternal age of the women at
study start was 31 (range 21–38) years and their pre-pregnancy
BMI was 24 (range 18–29) kg/m2. Most women had a high
socio-economic status: 80% went to college or university.
Before the study start, twenty-six women (72%) took a multi-
vitamin, containing vitamin D3 or vitamin D3 supplements,
containing 5–20 µg of vitamin D3/d. The women estimated to
spend 1 h outside on a weekday, and 2 h on a weekend day,
depending on the weather. We found no differences between
20GW and 4 weeks PP (data not shown). A total of thirty-four
women used a sunscreen with sun protection factor (SPF) 30.
Maternal 25-hydroxyvitamin D concentration
Fig. 2 shows the dose–response curve for plasma 25(OH)D.
Online Supplementary Table S1 contains the corresponding
data. A median 25(OH)D of 85 (range 25–131) nmol/l was
found for all women at 20GW. There were no between-group
differences (P= 0·374). At 36GW, 25(OH)D had increased in
group C (P< 0·017), while we noticed a trend in the others.
The medians for 25(OH)D were 82 (range 55–143) nmol/l in
group A, 111 (range 94–130) nmol/l in group B, 120 (range
88–157) nmol/l in group C and 118 (range 51–148) nmol/l in
group D. There were between-group differences (P< 0·050).
Compared with 36GW, 25(OH)D at 4 weeks PP had decreased
in groups A, B and C (P< 0·017), while there was a trend in
group D. The medians were 65 (range 43–96) nmol/l in
group A, 86 (range 76–105) nmol/l in group B, 84 (range
72–127) nmol/l in group C and 99 (range 52–122) nmol/l in
group D. There were between-group differences (P< 0·050).
We did not observe 25(OH)D values of 250 nmol/l or above at
any time. One woman assigned to the highest supplemental
dose (group D; 85 µg vitamin D3/d) exhibited 25(OH)D con-
centrations of 61, 51 and 52 nmol/l at 20GW, 36GW and
4 week PP, respectively. She was also assigned to the highest
fish oil intake, to which she also did not react.
Dose needed to reach vitamin D sufficiency (80–249nmol
25-hydroxyvitamin D/l)
Fig. 3 shows the percentage of participants with plasma 25(OH)D
above 80nmol/l at 20GW, 36GW and 4 weeks PP. We found
that 35µg vitamin D3/d or higher was needed to increase 25(OH)D
to adequacy (80–249nmol/l) in >97·5% of the participants at
36GW, while >85µg/d was needed to reach the same criterion at
4 weeks PP. Online Supplementary Table S2 shows the numbers of
participants with plasma 25(OH)D within the employed categories
of vitamin D status at 20GW, 36GW and 4 weeks PP. The parent
vitamin D concentration of the one woman assigned to the highest
supplemental dose and showing no 25(OH)D increment was
below the limits of quantification at all sampling points.
Dependence of plasma 25-hydroxyvitamin D increments
on baseline status and dose
Fig. 4(a) shows, for each of the supplemented groups A–D, the
relation between plasma 25(OH)D at 20GW and the plasma
25(OH)D increments from 20GW to 36GW. The increments
were found to relate to 25(OH)D concentration at 20GW.
Independent of dose, there were higher 25(OH)D increments at
low baseline status. The increments diminished gradually with
dose, suggesting that plasma 25(OH)D saturation was reached
at the higher dose. Although all participants reported com-
pliance with the protocol, six women in group A, one woman in
group B and two women in group D exhibited negative plasma
25(OH)D increments. Analogously, Fig. 4(b) shows the relation
between baseline plasma 25(OH)D concentration and the
plasma 25(OH)D increments from 20GW to 4 weeks PP. Also
here, the increments related to baseline 25(OH)D concentra-
tion, while the increments diminished with dose.
Association between plasma 25-hydroxyvitamin D
concentration and possible confounders
As shown in Fig. 4(a) and (b), GEE analysis confirmed that the
increases in plasma 25(OH)D concentration were inversely
related to the initial 25(OH)D concentration (P< 0·001). GEE also
showed that the month of year followed a second-order poly-
nomial (P< 0·001). Furthermore, GEE showed positive associa-
tions between the change in plasma 25(OH)D and visit (linear
and quadratic combination, following a parabolic association
P< 0·001), vitamin D3 dosage (P< 0·001) and age (P< 0·007).
Negative associations were found between increment in plasma
25(OH)D and BMI (P< 0·006), time spent outdoor during the
weekends (P< 0·007) and duration of pregnancy (P< 0·008). The
model fit was significant: Wald χ2 test was 248·29 (P< 0·0001).
Maternal plasma parent vitamin D concentration
Fig. 5 shows the dose–response curves for the maternal plasma
parent vitamin D. At the study start, the median for parent
vitamin D for all women was ‘not detectable’ (nd) (range
nd–40) nmol/l. There were no between-group differences
(P= 0·154). At 36GW, parent vitamin D had increased in groups
B and C (P< 0·017). We noticed a trend in the other two groups.
The medians of parent vitamin D at 36GW were nd (range
nd–9) nmol/l in group A, 11 (range nd–39) nmol/l in group B,
34 (range 19–76) nmol/l in group C and 88 (range nd–
100) nmol/l in group D. There were between-group differences
(P< 0·050). Compared with 36GW, parent vitamin D at 4 weeks
PP had decreased in group C (P< 0·017), while we noticed a
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Table 2. Basic characteristics of the investigated mothers and their infants, who completed the study
(Medians and ranges; numbers and percentages)
Supplementation group
All (n 36) A (n 9) B (n 9) C (n 11) D (n 7)
Variable Dimensions Median Range Median Range Median Range Median Range Median Range P*
Maternal characteristics
Age (years) 31 21–38 32 27–37 31 26–36 32 25–36 30 21–38 0·667
Pre-pregnancy BMI (kg/m2) 24 18–29 24 19–29 24 18–28 22 19–27 24 21–26 0·896
Para n 1 0–2 1 0–2 1 0–2 1 0–2 1 0–2 0·892
Gestation n 2 0–5 2 1–5 2 1–4 2 0–3 2 1–5 0·532
Gestation duration (weeks) 41 37–42 41 40–42 40 38–42 40 37–41 40 38–42 0·149
Socio-economic status
Married/living together n (%) 36 100 9 100 9 100 11 100 7 100 1·000
Household number n 3 2–4 3 2–4 3 2–4 3 2–4 3 2–4 0·851
Education 0·322
High school, intermediate vocational or less n (%) 7 20 – 2 22 4 36 1 17 –
College, university or higher n (%) 28 80 9 100 7 78 7 64 6 86 –
Annual household income 0·130
€10000–€30000 n (%) 7 20 1 11 3 33 1 9 2 28 –
€30000–€50000 n (%) 14 39 4 44 4 44 5 45 1 14 –
€50000 or more n (%) 15 42 4 44 2 22 5 45 4 57 –
Other
Vitamin D3 containing (multi-vitamin) supplement n (%) 26 72 8 89 6 67 8 73 4 57 0·670
Vitamin D3 dose µg/d 10 5–20 10 10–20 10 5–10 10 10–10 10 10–10 0·315
Season of enrolment 0·870
Spring n (%) 5 14 1 11 2 22 1 9 1 14
Summer n (%) 17 47 6 67 4 45 4 36 3 43
Autumn n (%) 10 28 1 11 3 33 4 36 2 29
Winter n (%) 4 11 1 11 – 2 18 1 14
Estimated time spent outside at study start
Weekday Hours 1 0–4 1 0–4 2 0–3 1 0–4 1 0–3 0·679
Weekend-day Hours 2 0–5 2 0–4 2 1–5 2 1–4 3 1–5 0·419
Easily sunburned n (%) 12 33 4 44 3 33 2 18 3 42 0·498
Use of sunscreen n (%) 34 94 8 89 9 100 11 100 6 86 0·436
SPF factor sunscreen 30 10–50 30 10–50 20 20–50 30 10–50 30 10–50 0·750
Use of clothes against sunlight n (%) 8 22 1 11 2 22 3 27 2 29 0·748
Infant characteristics
Birth weight (g) 3790 2440–5020 3790 2870–5020 3965 2440–4640 3750 3070–4610 3870 3440–4695 0·860
Sex (% male) 17 47 3 33 4 44 7 64 3 43 0·579
Lactation duration (weeks) 4·4 3·5–5·3 4·4 3·5–4·7 4·4 3·7–5·3 4 3·6–4·9 4·6 4·0–5·1 0·033
Weight (kg) 4·5 3·6–5·7† 4·4 3·9–5·6 4·7 3·9–5·7 4·4 4·0–5·2 5·2 3·6–5·6 0·672
* The total between-group differences were analysed with the Kruskal–Wallis test for continuous data and the χ2 test for nominal data. A P value of 0·05 was considered significant.
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trend in the others. At 4 weeks PP, parent vitamin D was
5 (nd–12) nmol/l in group A, 14 (nd–34) nmol/l in group B, 31
(8–52) nmol/l in group C and 38 (nd–71) nmol/l in group D.
There were between-group differences (P< 0·050). The corre-
sponding data can be found in online Supplementary Table S1.
Milk antirachitic activity
Fig. 6 shows the dose–response curves for the milk ARA. Online
Supplementary Table S3 presents the corresponding data. The
medians of milk ARA at 4 weeks PP were 33 (range 20–57) IU/l
in group A, 83 (range 48–145) IU/l in group B, 150 (range 45–
1089) IU/l in group C and 156 (range 26–309) IU/l in group D.
We found significant differences (P< 0·050) for milk ARA
between groups A and C, and groups A and D. None of the
groups reached a median milk ARA of 513 IU/l, but there was
one milk sample in group C that exceeded the IOM AI. Rea-
nalysis of this sample confirmed the high concentration (1089 v.
1030 IU/l). The linear relation between vitamin D3 dosage and
milk ARA at 4 weeks PPwasmilk ARA (IU/l)=29·5+2·27×vitamin D3
dosage (µg/d), R2 0·109. Employing this relation, we estimate
that the vitamin D3 dose needed to reach the 513 IU/l milk ARA
target at 4 weeks PP amounts to 213 µg/d. We found relations
(P< 0·001) between both maternal plasma parent vitamin D
(r 0·870) and 25(OH)D (r 0·685) with milk ARA.
Possible adverse effects
Online Supplementary Table S1 presents the data at the various
visits of plasma Ca, plasma phosphate and the urine Ca:creati-
nine ratio. Plasma Ca and phosphate were below the upper
limits of their reference ranges, as employed in our laboratory,
while the urinary Ca:creatinine ratio was in agreement with
those reported by Steegers et al.(45) for pregnant and lactating
women. None of the groups exhibited longitudinal changes in
these parameters of potential vitamin D toxicity.
Discussion
As a primary aim of our ZOOG study, we were interested to
































Fig. 2. Relations between the vitamin D dosages and plasma 25-hydroxyvitamin D (25(OH)D) concentration at 20 gestational weeks (GW), at 36GW and at 4 weeks
postpartum (PP). The participants took 10 (group A), 35 (group B), 60 (group C) or 85 (group D) µg vitamin D3/d from 20GW to 4 weeks PP. The subgroups did not
differ in plasma 25(OH)D at 20GW. Horizontal lines indicate the cut-offs at 50 and 80nmol/l. * Significance in that group compared with the previous outcome.














































Fig. 3. Percentages participants with plasma 25-hydroxyvitamin D (25(OH)D)
above the employed cut-off value for vitamin D adequacy at 80 nmol/l at 20
gestational weeks (GW), 36GW and 4 weeks postpartum (PP). Time: ,
20 GW; , 36 GW and , 4 weeks PP.
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Daily vitamin D dose
A: 10 μg (n 9)
B: 35 μg (n 9)
C: 60 μg (n 11)
D: 85 μg (n 7)
A: 10 μg (n 9)
B: 35 μg (n 9)
C: 60 μg (n 11)
D: 85 μg (n 7)
A: 10 μg (n 9): R2 Linear = 0.285
B: 35 μg (n 9): R2 Linear = 0.756
C: 60 μg (n 11): R2 Linear = 0.731
D: 85 μg (n 11): R2 Linear = 0.122
A: 10 μg (n 9): R2 Linear = 0.588
B: 35 μg (n 9): R2 Linear = 0.832
C: 60 μg (n 11): R2 Linear = 0.828
D: 85 μg (n 7): R2 Linear = 0.335
Daily vitamin D dose
A: 10 μg (n 9)
B: 35 μg (n 9)
C: 60 μg (n 11)
D: 85 μg (n 7)
A: 10 μg (n 9)
B: 35 μg (n 9)
C: 60 μg (n 11)


























































Fig. 4. (a) Relations between baseline plasma 25-hydroxyvitamin D (25(OH)D) concentrations at 20 gestational weeks (GW) and plasma 25(OH)D increments
(Δ 25(OH)D in nmol/l) from 20 to 36GW in the four dosage groups. (b) Relations between baseline plasma 25(OH)D concentrations at 20GW and plasma 25(OH)D
increments from 20 to 4 weeks postpartum (PP). Relations are given for groups A–D who received 10 (group A), 35 (group B), 60 (group C) and 85 (group D) µg
vitamin D3/d from 20GW to 4 weeks PP. The increments related negatively to baseline 25(OH)D concentration and diminished with dose. Zero increments occurred































Fig. 5. Relations between the vitamin D dosages and plasma parent vitamin D at 20 gestational weeks (GW), at 36GW and at 4 weeks postpartum (PP). The
participants took 10 (group A), 35 (group B), 60 (group C) and 85 (group D) µg vitamin D3/d from 20GW to 4 weeks PP. * Significance in the group compared with the
previous group outcome. † Potential non-user. Daily dose vitamin D – 10 µg (n 9) (missing data from one woman at 4 weeks PP), 35 µg (n 9), 60 µg (n 11) and
85 µg (n 7).
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concentrations that would be reached by supplementing
pregnant women with 10, 35, 60 and 85 µg vitamin D3/d from
20GW up to 4 weeks PP, and notably the corresponding milk
ARA that would be reached at 4 weeks PP. The investigated
women had relatively high 25(OH)D at 20GW (median 85;
range 25–131 nmol/l). We found that, in general, the supple-
ments increased both plasma parent vitamin D (Fig. 5) and
25(OH)D (Fig. 2) in a seemingly dose-dependent manner,
from 20GW to 36GW, but not from 36GW to 4 weeks PP. The
dose-dependent increase in plasma 25(OH)D was confirmed
by GEE analysis. Dosages of 35 µg vitamin D3/d or higher
were needed to augment 25(OH)D to adequacy (80–
249 nmol/l) in >97·5% of the participants at 36GW, while
>85 µg/d was needed to reach the same criterion at 4 weeks
PP (Fig. 3). The increments of 25(OH)D from 20 to 36GW
(Fig. 4(a)) and from 20GW to 4 weeks PP (Fig. 4(b)) related
inversely to the 25(OH)D concentration at 20 GW and dimin-
ished with dose. The supplements also caused a dose-
dependent increase in the milk ARA at 4 weeks PP (Fig. 6).
Except for one, none of the women reached a milk ARA of
513 IU/l, which corresponds with the AI of the IOM for
6 months old infants. Using a linear equation, it was estimated
that this target would require a vitamin D3 supplemental dose
of 213 µg/d.
Baseline vitamin D status and achievement of the 80nmol/l
25-hydroxyvitamin D/l cut-off
The median 25(OH)D concentration of 85 (range 25–
131) nmol/l at 20GW (baseline) was higher than expected on
forehand. Two studies, the ‘KOALA’(46) and ‘Generation R’(12),
both conducted with pregnant women in the Netherlands,
found lower 25(OH)D of 44 (±18) and 65 (interquartile range:
43–87) nmol/l, respectively. In our study, only one woman
(3%) was classified as vitamin D deficient at enrolment, while
only three (8%) exhibited vitamin insufficiency. The ‘Genera-
tion R’ study revealed that among the women with European
ethnic background, 7% had vitamin D deficiency and 25% had
vitamin D insufficiency (25–49·9 nmol/l). The high vitamin D
status of our study group is likely explained by the high socio-
economic status of the recruited participants. They might have
been more health conscious than their counterparts in the
general population. Most of them (72%) used a daily vitamin D
supplement of 10 (range: 5–20) µg before the study start.
We found that all employed vitamin D3 dosages seemed
effective in increasing the prevalence of vitamin D adequacy
from 20 to 36GW, but this was not the case for the comparison of
20GW with 4 weeks PP. Obviously, it seems easier to reach
vitamin D adequacy in pregnancy than in lactation. The dis-
crepancy might be explained by vitamin D mobilisation from
stores during pregnancy (see below). A dosage of 35 µg vitamin
D3/d or higher was needed to reach vitamin D adequacy in
>97·5% of the participants at 36GW, while >85µg/d was needed
to reach this criterion at 4 weeks PP. However, we believe one
participant in the highest supplementation group to be non-
compliant, on basis of her unresponsiveness on plasma 25(OH)D,
parent vitamin D and fish oil results. When excluding this parti-
cipant, we found that 85µg/d was sufficient to reach vitamin D
adequacy in >97·5% of the participants at 4 weeks PP.
Courses of plasma 25-hydroxyvitamin D and parent
vitamin D during the study
Supplementation with vitamin D3 dose dependently maintained
or increased plasma 25(OH)D concentration at the pregnancy’s
end (Fig. 2). This finding is in line with March et al.(20) who
demonstrated a dose-dependent 25(OH)D increase following
administration of 10, 25 and 50 µg vitamin D/d from 13 to
24GW until 36GW. Upon continuing supplementation, their
study subjects maintained or even increased their 25(OH)D
concentration from 36GW to 8 weeks PP. Unlike March et al.,
we found that the 25(OH)D concentration decreased, or tended
to decrease, from 36GW to 4 weeks PP (Fig. 2). A similar initial
increase during pregnancy and a subsequent decrease during
lactation was observed for the parent vitamin D (Fig. 5). An
explanation could be non-compliance shortly after giving birth,
however, the women in our study reported >75% compliance
to the supplements during the whole study. Although the GEE
revealed that ‘month of the year’ followed a second-order
polynomial, evaluation of the individual pregnancy periods
suggested that it is unlikely that these courses are explained by
seasonal cycling of vitamin D status, with highest 25(OH)D
concentration in the Netherlands occurring around early
August(37). The women estimated that during the study they
spent 1 h outside on a weekday and 2 h on a weekend day,
depending on season and weather. In the Netherlands, during
November to March, the required wavelength of sunlight






























Fig. 6. Relations at 4 weeks postpartum (PP) between vitamin D dosages
and milk antirachitic activity (ARA). The participants took 10 (group A), 35
(group B), 60 (group C) or 85 (group D) µg vitamin D3/d from 20 gestational
weeks to 4 weeks PP. The linear relation between the vitamin D dosages and
milk ARA was y= 29·5+ 2·27x (x in µg and y in IU/l). The calculated vitamin D
dosages needed to reach the target of 513 IU/l was 213 µg/d. The horizontal
line indicates the infant adequate intake (AI) of the Institute of Medicine (IOM)
at a milk ARA of 513 IU/l (i.e. 10 µg vitamin D/d at 780ml milk/d). Except for one
in group C, none of the mothers reached the IOM AI. * Significance (P< 0·05).
The increasing ARA with dose is mainly on account of increasing vitamin D
concentrations.
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Furthermore, from April until October, vitamin D synthesis is
highest/possible between 11.00 and 15.00 hours. The Dutch
Health Council calculated that persons with skin type II, who
spend 21min/d outside between 11.00 and 15.00 hours, while
wearing summer clothes, would produce between 6 and 7 µg
vitamin D(17). However, as many variables(47), such as clothing,
sunscreen, air pollution and clock time, influence vitamin D
synthesis in the skin, it is impossible to estimate the vitamin D
contribution from sunlight exposure. Furthermore, pregnant
women are advised to minimise sunbathing and to use a
sunscreen. In all, thirty-four of the women reported to use a
sunscreen upon going outside, with a median SPF of 30. If
applied correctly, sunscreen protection factor 30 could reduce
the vitamin D production in the skin by 95–98%(48). In conclu-
sion, we consider it unlikely that sunlight exposure explains the
observed courses of parent vitamin D and 25(OH)D in our study.
In a previous cross-sectional study of unsupplemented tradi-
tionally living Tanzanian women, we found higher 25(OH)D in
pregnancy but similar concentrations at 3 d and 3 months PP,
when compared with non-pregnant counterparts. These women
are exposed to year-long abundant sunshine.We are aware of one
other study in which 25(OH)D increased during pregnancy and
fell after delivery(49). The higher 25(OH)D of unsupplemented
mothers during pregnancy contrasts with the vast majority of
literature data. Some authors showed higher concentrations(50–52),
but themost showedno change (Grant(19) placebo group) or even
declining concentrations(53–56). The discrepancies may relate to
different magnitudes of maternal vitamin D stores.
We previously suggested(38) that the higher 25(OH)D during
pregnancy in Tanzania might be caused by the well-known
higher circulating vitamin D binding protein (DBP) concentra-
tions, which in turn may be driven by oestrogens(57,58). DBP has
high affinity for 25(OH)D and to lesser extent for the parent
vitamin D and the 1,25(OH)2D hormone
(59). While the
mechanism underlying the 2- to 3-fold 1,25(OH)2D increases
during pregnancy is unclear(10), it is possible that induction of
DBP extracts parent vitamin D from adipose tissue stores(38) and
25(OH)D from muscle(60,61) for subsequent transplacental
transfer. Mobilisation of parent vitamin D from adipose tissue
during pregnancy might be facilitated by the reducing insulin
sensitivity in the second and third trimesters(57), while it has
been suggested that 25(OH)D is mobilised from muscle by
physical activity(60). Uptake of DBP-bound 25(OH)D in the
placenta may be facilitated by the megalin–cubilin system(59),
while parent vitamin D, because of its higher free fraction(59),
may more intensively cross by diffusion. Accumulation of
the parent vitamin D may take place in the rapidly growing,
vitamin D-naive, fetal adipose tissue compartment. This com-
partment amounts to about 0·35 kg at birth(62), has been pre-
dominantly synthesised from maternal glucose and does not
become mobilised during intrauterine life.
Dependence of plasma 25-hydroxyvitamin D increments
on baseline status and dose
We found that the increments of plasma 25(OH)D from 20GW
to 36GW (Fig. 4(a)) and from 20GW to 4 weeks PP (Fig. 4(b))
relate inversely to the plasma 25(OH)D at 20GW. In other
words, the higher the 25(OH)D level at 20GW, the lower the
25(OH)D response, irrespective of vitamin D3 supplemental
dose. Such saturation effects of plasma 25(OH)D during vitamin
D3 supplementation have been previously observed
(63–65),
either suggesting increasing storage, deactivation (e.g.
24-hydroxylation(66)) or both. It seems that at high baseline
25(OH)D concentration vitamin D3 supplementation might
even cause a decrease, which is in line with previous find-
ings(67). Especially at low supplemental dosages, such a
decrease might, however, also be caused by supplement use
before the study, incompliance, analytical variation, uncon-
trolled sunlight exposure, BMI, age and influence of stores.
Altogether we suggest that next to vitamin D’s immune func-
tion(68), the deviant vitamin D physiology in pregnancy aims at
the building of infant stores.
Milk antirachitic activity
The daily vitamin D3 dosages provided by us during pregnancy
and lactation gave rise to a dose-dependent increase in the milk
ARA, as measured at 4 weeks PP (Fig. 6). Except for one woman
with a milk ARA of 1089 IU/l, none of the participants reached
the 10 µg/d vitamin D output consistent with the IOM AI for
0–6 months old infants, and as translated to a milk ARA of
513 IU/l. We previously reported that vitamin D unsupple-
mented lactating women inhabiting various countries, including
women with lifetime abundant sunlight exposure and high
vitamin D status, had milk ARA ranging from 1 to 247 IU/l and
did not reach this output either(27).
Using linear extrapolation, we estimated that a daily sup-
plemental dose of 213 µg would be needed to reach a milk ARA
of 513 IU/l, which seems in reasonable agreement with the
study of Wagner et al.(31). They supplemented with 160 µg
vitamin D3/d for 6 months during lactation to find a milk ARA of
874 IU/l at the study end(31).
Taken together, it seems that a daily dose of 50 µg vitamin
D3/d
(19,30) and likely up to 85 µg/d as in the present study,
provided during pregnancy and/or lactation, is unable to
increase the milk ARA to the IOM AI for 0–6 months old infants.
Potentially adverse effects
None of the women reported adverse effects. Laboratory signs
of vitamin D toxicity are hypercalciuria, hypercalcaemia and
low serum PTH. Plasma 25(OH)D concentration did not exceed
250 nmol/l at any sampling point, while plasma Ca and phos-
phate remained below the upper limits of the reference ranges
employed in our laboratory. The urinary Ca:creatinine ratios
were in agreement with those reported by Steegers et al.(45) for
pregnant and lactating women. We did not analyse plasma
PTH, but other studies did not detect abnormalities following
supplementation with up to 160 µg vitamin D3/d
(31,32).
Limitations
The high plasma 25(OH)D concentrations in our study group at
20GW, exhibiting almost no vitamin D deficiency or
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insufficiency, limits our findings to women with high vitamin D
status at baseline. We nevertheless found that even these
women needed vitamin D3 supplements to maintain a high
vitamin D status. Other limitations include the small subject
numbers per supplemental group, high socio-economic status
and the mere European ethnic background of the women. We
chose to use four different dosages as opposed to larger sub-
groups with less dose variation. Confounding factors that might
have influenced inter-individual variation are BMI, age, season,
clothing and behaviour with regard to sunlight exposure. We
did find that month of year influenced the 25(OH)D increase.
Another limitation is that we did not collect infant (cord) blood
samples.
Conclusions
Both plasma parent vitamin D and 25(OH)D increased see-
mingly dose dependent from 20 to 36GW and decreased
subsequently from 36GW to 4 weeks PP. Dosages of 35 µg
vitamin D3/d or higher were needed to increase 25(OH)D to
adequacy in >97·5% of participants at 36 GW, while >85 µg/d
was needed to reach this target in >97·5% of participants at
4 weeks PP. The lower dose needed in pregnancy may relate
to mobilisation of maternal vitamin D stores during preg-
nancy. The magnitude of the 25(OH)D increment from 20 to
36GW and from 20GW to 4 weeks PP diminished with dose
and related inversely to 25(OH)D at 20 GW. Milk ARA at
4 weeks PP increased in a dose-dependent manner. However,
except for one, none of the women reached a milk ARA of
513 IU/l. A 213 µg/d supplement may be needed to reach the
infant AI.
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